Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis
Launched by MEIR MEDICAL CENTER · Jan 4, 2011
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Autologous platelet-secreted growth factors (GFs) may have therapeutic effects in osteoarthritis (OA) capsular joints via multiple mechanisms. The investigators aim is to examine the effect of a platelet-derived preparation rich in growth factors(PRGFs) in OA of the knee, using parameters of pain, function, quality of life and safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 40-75 years old
- • diagnosed Oa of the knee more then 1 year
- • no knee deformation
- Exclusion Criteria:
- • mental of physical disabilities
- • pregnancy
- • deformities of the knee
Trial Officials
Lior Laver, MD
Principal Investigator
Meir Medical Center
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kfar Saba, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
